A new analysis of the Novavax PREVENT-19 clinical trial, conducted by researchers with the COVID-19 Prevention Network (CoVPN), concluded that this recombinant protein vaccine produced an antibody response comparable to mRNA vaccines and, if authorized, could help bolster global vaccine supplies, according to a news release.
As previously reported, the clinical trial found that two doses of the Novavax vaccine were 90% effective at preventing symptomatic COVID-19 among almost 30,000 randomized participants between December 27, 2020 and February 18, 2021.
The CoVPN analysis, posted on medRxiv, showed that the Novavax vaccine produced the same antibody markers as mRNA vaccines and they performed well as “correlates of protection,” says Peter Gilbert, PhD, corresponding author of the study and a biostatistician at Fred Hutchinson Cancer Center, where CoVPN is headquartered.
